APTO 253

Drug Profile

APTO 253

Alternative Names: APTO-253; LOR-253; LOR-253 HCl; LT-253

Latest Information Update: 16 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lorus Therapeutics
  • Developer Aptose Biosciences
  • Class Antineoplastics; Imidazoles; Indoles; Phenanthrolines; Small molecules
  • Mechanism of Action Apoptosis stimulants; GKLF protein stimulants; Proto oncogene protein c-myc inhibitors; Transcription factor MTF-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes
  • Suspended Haematological malignancies; Non-small cell lung cancer; Solid tumours

Most Recent Events

  • 11 Jul 2018 Phase-I clinical trials in Myelodysplastic syndromes and Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV)
  • 29 Jun 2018 US FDA lifts the clinical hold on phase Ib trial in Acute myeloid leukemia or Myelodysplastic syndromes
  • 10 May 2018 Aptose Biosciences plans to submit findings from studies of new clinical supply of APTO 253 to US FDA in the second quarter of 2018 (to re-initiate a suspended phase I trial for Acute myeloid leukaemia or Myelodysplastic syndrome)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top